Human immunodeficiency virus drug resistance: 2018 recommendations of the International Antiviral Society–USA panel

HF Günthard, V Calvez, R Paredes… - Clinical Infectious …, 2019 - academic.oup.com
Background Contemporary antiretroviral therapies (ART) and management strategies have
diminished both human immunodeficiency virus (HIV) treatment failure and the acquired …

Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study

LE Hermans, M Moorhouse, S Carmona… - The Lancet infectious …, 2018 - thelancet.com
Background Antiretroviral therapy (ART) that enables suppression of HIV replication has
been successfully rolled out at large scale to HIV-positive patients in low-income and middle …

Persistent low-level viremia while on antiretroviral therapy is an independent risk factor for virologic failure

C Joya, SH Won, C Schofield, T Lalani… - Clinical Infectious …, 2019 - academic.oup.com
Background Whether persistent low-level viremia (pLLV) predicts virologic failure (VF) is
unclear. We used data from the US Military HIV Natural History Study (NHS), to examine the …

[HTML][HTML] Influencing factors and adverse outcomes of virologic rebound states in anti-retroviral-treated individuals with HIV infection

D Yuan, M Li, Y Zhou, L Shi, J Lu, G Fu… - Journal of Virus Eradication, 2023 - Elsevier
Antiretroviral therapy (ART) aims to inhibit HIV replication, decrease CD4 T cell loss, and
immune function recovery in order to reduce the morbidity and mortality associated with the …

Drug resistance profile among HIV-1 infections experiencing ART with low-level viral load in Guangdong China during 2011–2022: a retrospective study

Y Lan, X Ling, X Deng, Y Lin, J Li, L Li… - Infection and Drug …, 2023 - Taylor & Francis
Background Antiretroviral therapy (ART) efficiently reduces the morbidities and mortalities
caused by HIV-1 infection and prevents the HIV epidemic. However, virologic failure (VF) …

Impact of low-level viremia with drug resistance on CD4 cell counts among people living with HIV on antiretroviral treatment in China

P Liu, Y You, L Liao, Y Feng, Y Shao, H **ng… - BMC infectious …, 2022 - Springer
Abstract Background Maintaining plasma HIV RNA suppression below the limit of
quantification is the goal of antiretroviral therapy (ART). When viral loads (VL) remain in low …

Effect of rifampin on the single-dose pharmacokinetics of oral cabotegravir in healthy subjects

SL Ford, K Sutton, Y Lou, Z Zhang… - Antimicrobial agents …, 2017 - journals.asm.org
Drug-drug interactions between antiretroviral medications and rifampin complicate the
treatment of HIV and tuberculosis coinfection. This study evaluated the effect of rifampin on …

The prevalence of low-level viraemia and its association with virological failure in people living with HIV: a systematic review and meta-analysis

S Zhao, W Wang, S Li, J He, W Duan… - Emerging Microbes & …, 2025 - Taylor & Francis
Low-level viraemia (LLV) following antiretroviral therapy (ART) in people living with HIV
(PLWH) has not received sufficient attention. To the determine the prevalence of LLV and its …

[HTML][HTML] Transcriptome analysis of CD4+ T cells from HIV-infected individuals receiving ART with LLV revealed novel transcription factors regulating HIV-1 promoter …

J Chen, Y He, H Zhong, F Hu, Y Li, Y Zhang, X Zhang… - Virologica Sinica, 2023 - Elsevier
Some HIV-infected individuals receiving ART develop low-level viremia (LLV), with a plasma
viral load of 50–1000 copies/mL. Persistent low-level viremia is associated with subsequent …

Persistent low-level viraemia in antiretroviral treatment-experienced patients is not linked to viral resistance or inadequate drug concentrations

R Palich, M Wirden, G Peytavin, MP Lê… - Journal of …, 2020 - academic.oup.com
Objectives To assess genotypic sensitivity scores (GSSs), plasma antiretroviral
concentrations (PACs) and immunovirological outcomes at Week 96 (W96) in patients with …